Prostate cancer is the most common cancer and the second cause of cancer-related deaths in males in the United States. The development of novel chemopreventive strategies may be extremely helpful to prevent and arrest the development of this neoplasm. Andrographolide, a labdane diterpenoid that is the main bioactive component of the medicinal plant Andrographis paniculata, has anti-inflammatory and anticarcinogenic properties. In this study, we sought to examine the effect of andrographolide on PC3 and LNCaP prostate cancer epithelial cells. Andrographolide significantly inhibited PC3 cell growth at a concentration of 10µM after 24 h of treatment (P < 0.001), and inhibited LNCaP cell growth at a concentration of 15 µM after 24 h of treatment (P < 0.001). Wound healing assay and boyden chamber experiments were performed in order to determine whether andrographolide had an effect on migration and invasion. When PC3 and LNCaP cells were treated with andrographolide the total number of migrating and invading cells was significantly reduced (P < 0.001) when compared to control. To study possible anti-migration and anti-invasion mechanisms of andrographolide on PC3 and LNCap cells, we examined the expression of various adhesion molecules. Andrograholide significantly decreased the expression of vimentin in PC3 and LNCap treated cells. However, PC3 and LNCaP cells treated with andrographolide had increased expression levels of occludin and ZO-1. In addition, immunofluorescence and western blot analysis showed that PC3 and LNCaP cells treated with andrographolide had decresased expression levels of MMP-11. Our results suggest that the anti-migration and anti-invasion effects of andrographolide in PC3 and LNCaP cells may be associated with alterations in the expression of occluding, ZO-1 and MMP-11.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 590. doi:1538-7445.AM2012-590

©2012 American Association for Cancer Research
2012